Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIncanthera Regulatory News (INC.PL)

Share Price Information for Incanthera (INC.PL)

Share Price is delayed by 15 minutes
Get Live Data
1.90    0.50 (35.71%)
Bid:
1.70
Ask:
2.10
Spread: 0.40 (23.529%)
Market Cap: £2.62m
INC.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Incanthera Share Chart

SKIN + CELL TO LAUNCH

6 Aug 2025 07:00

RNS Number : 1274U
Incanthera PLC
06 August 2025
 

 

 

 

06 August 2025

Incanthera plc

 

("Incanthera" or the "Company")

 

SKIN + CELL TO LAUNCH on 11 AUGUST 2025

 

Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology is pleased to announce the launch of Skin + CELL, our premium skincare range, on Monday 11 August 2025.

 

Skin + CELL's unique skincare range will, for the first time, be available for sale through our dedicated commercial website: https://www.skinandcell.com/, launching with face, body, hand, face serum and eye cream.

 

On 30 June 2025, the Company announced that Skin + CELL would be launching in early August 2025 via a Direct to Consumer ("DTC") route. This followed the signing of a business agreement with a global DTC marketing agency (the "Agency") announced on 2 June 2025.

 

Launching initially via a digital marketing strategy, executed by influencer and brand ambassador campaigns, sales of Skin + CELL will be satisfied through the dedicated Skin + CELL e-commerce website, which has been designed to market the full product range, and to receive sales orders.

 

In preparation for launch, the Agency has commenced populating social media sites with posts that set the tone and visual for the brand, across platforms Instagram Tik Tok, Facebook and YouTube. Teaser posts that highlight a scientifically different skincare range are being filtered across these platforms.

 

Click on the links below to view the start of the campaign:

 

SHOPskinandcell.com

Instagram instagram.com/skin_and_cell

TikToktiktok.com/@skin_and_cell

Facebookfacebook.com/skinandcell

 

YouTubewww.youtube.com/@skin_and_cell

 

 

 

Global teams, established and managed by the Agency, are working across UK & Europe, US, and Asia to introduce Skin + CELL via social media influencers and brand ambassadors with an initial reach in excess of 40 million followers across the global campaign.

 

As the campaign rolls out further through August, September and months beyond, across different media platforms, supported with a two-stage video advertisement, an ever-growing network of brand ambassadors and influencers promoting Skin + CELL means a potential target audience of approximately 150 million people.

 

The campaign also builds into a wider digital and traditional campaign that targets industry specialists and journalists in beauty and personal care publications.

 

The Company will continue to notify further key milestones in the global launch and further roll out of Skin + CELL across social, digital and traditional media campaigns from launch date, including additional links to access media posts.

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

For further information please contact:

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

 

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600

Aquis Exchange Corporate Adviser: 

Cairn Financial Advisers LLP

Jo Turner / Liam Murray / Ed Downes

 

+44 (0) 20 7213 0880

Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney

+44 (0) 20 3650 3650/51

 

Notes to Editors

 

About Incanthera plc

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

About Skin + CELL 

Skin + CELL is Incanthera's luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

 

Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

 

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXLELLBEVLFBBX
12
Date   Source Headline
4th Jun 20267:00 amRNSCorporate Update
31st Mar 20267:00 amRNSCommercial Update
11th Dec 20257:20 amRNSHalf-year Report
17th Nov 20257:00 amRNS-RAquis Showcase Investor Presentation
10th Nov 202511:04 amRNS-RAGM 2025 Presentation Materials
7th Nov 20252:30 pmRNSResult of AGM
6th Nov 20257:00 amRNSAGM 2025 Update
16th Oct 202510:15 amRNS-RProactive Investor Forum Presentation
14th Oct 20257:00 amRNSNotice of AGM
6th Oct 20257:00 amRNS-RInvestor Presentation
30th Sep 20258:15 amRNSFinal Results
11th Aug 20257:00 amRNSSKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
6th Aug 20257:00 amRNSSKIN + CELL TO LAUNCH
9th Jul 20257:00 amRNSHolding(s) in Company
30th Jun 20257:00 amRNSSubscription, Directors' Dealing and RPT
18th Jun 20257:00 amRNSNew Findings on Protective Effects of Skin + CELL
2nd Jun 20257:00 amRNSDirect To Customer Agency Agreement Completed
22nd May 20257:00 amRNSCommercial Update
8th Apr 20257:00 amRNSHolding(s) in Company
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
28th Mar 20257:00 amRNSCommercial Update
25th Mar 20253:08 pmRNSResolution of Allegations of Patent Infringement
18th Dec 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSCommercial Update
29th Oct 20247:00 amRNSFurther re: Commercial Update
17th Oct 20241:05 pmRNSResult of AGM
26th Sep 20247:00 amRNSCommercial Update
25th Sep 20247:00 amRNSNotice of AGM
9th Sep 20247:01 amRNSExtension of Warrants
27th Aug 20247:00 amRNSFinal Results
14th Aug 20247:00 amRNSExercise of Warrants
11th Jul 20247:00 amRNSCommercial Order Update
25th Jun 20244:00 pmRNSHolding(s) in Company
21st Jun 20242:45 pmRNSHolding(s) in Company
21st Jun 20248:00 amRNSCompletion of Subscription
20th Jun 202411:38 amRNSResult of Meeting
10th Jun 20247:00 amRNSAppointment of NED & Promotion to the Apex Segment
6th Jun 20244:20 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNSAQSE Webinar Presentation
3rd Jun 20247:00 amRNSCommercial Update and Subscription
16th May 20248:07 amRNSInvestor Presentation
25th Apr 20247:00 amRNSHolding(s) in Company
23rd Apr 20242:15 pmRNSFurther re: Exercise of Warrants
17th Apr 20247:00 amRNSFurther re: Exercise of Warrants
9th Apr 20243:00 pmRNSExercise of Warrants
25th Mar 20242:30 pmRNSInitiation of Analyst Research and IGTV Interview
25th Mar 20247:00 amRNSCommercial Update
22nd Feb 20247:00 amRNSGrant of Options
11th Jan 20247:00 amRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.